UNSPSC 51112019: Bosutinib

This classification denotes a tyrosine kinase inhibitor with the molecular structure C26H29CL2N5O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, 5018V4AEZ0 chemically known as 3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methyl-1-piperazinyl)propoxy)-, but more commonly known as bosutinib, which bears U.S. National Institutes of Health Compound Identifier 5328940. European Medicines Agency schedules Bosutinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29176.

The term BOSUTINIB is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 20, no. 3, 2006, list 56).

UNSPSC 51112019 Bosutinib, a Commodity code, encompasses state and local procurement of this targeted cancer therapy medication, typically acquired as part of broader pharmaceutical supply agreements rather than as standalone buys. State and local governments procure bosutinib primarily through cooperative purchasing alliances and state pharmaceutical contracts that consolidate demand across multiple agencies, health departments, correctional facilities, and participating jurisdictions. The work involves vendors certifying cGMP compliance and Drug Supply Chain Security Act (DSCSA) conformance, managing distribution through authorized pharmaceutical wholesalers with chargeback systems, and maintaining contractual relationships with multiple wholesaler tiers to ensure consistent availability and pricing transparency across member entities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP) on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including bosutinib, across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and submit detailed National Drug Code (NDC), SKU, UPC, strength, dosage form, and manufacturing location data. Evaluation weights pricing competitiveness at 75 percent, with fixed pricing, administrative compliance (5 percent each), EDI capability (5 percent), and a 3 percent administrative fee structure (5 percent). Products must be marketplace-available by May 15, 2026, with awarded contracts effective July 1, 2026 for a two-year term with optional extensions. The RFP requires commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, professional liability of $2,000,000, and products must carry FDA compliance and expiration dates at least one year from manufacture.